Eli Lilly profit beat helps ease investor concerns over growth

(Reuters) - Eli Lilly and Co posted a higher-than-expected fourth-quarter profit on Thursday on strong demand for diabetes drug Trulicity and psoriasis treatment Taltz, helping ease investor concerns over the impact of fierce competition for its growth products.Sales of Trulicity surged nearly 31% to $1.21 billion (920.57 million pounds) in the quarter, accounting for about a fifth of total sales and surpassing expectations of $1.15 billion, according to Refinitiv data. Taltz sales rose about..